Dermata Posts Narrower Loss in Q2
Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotech specializing in innovative dermatology therapies, released its earnings on August 13, 2025. The company’s primary news item was a narrower net loss than expected, with a GAAP loss per share of $1.66 compared to analyst estimates of $2.90. This improvement came as Dermata reduced its operating expenses, especially in research and development, after completing its pivotal Phase 3 STAR-1 clinical trial for XYNGARI™, its lead acne treatment candidate. Dermata’s cash position strengthened due to an $8.8 million financing round in the first half of 2025, providing a financial runway into the second quarter of 2026. Overall, the quarter showed significant clinical progress, effective cost containment, and improved cash resources, even as operating expenses shifted with development-stage priorities.
Source: Analyst estimates for the quarter provided by FactSet.
Dermata Therapeutics is focused on developing topical and transdermal treatments for chronic skin conditions using its Spongilla technology platform. The company’s lead product, XYNGARI™, is a once-weekly topical therapy made from the freshwater sponge Spongilla lacustris. The Spongilla platform also supports DMT410, a product targeting hyperhidrosis (excessive sweating) and aesthetic dermatology applications.
Source Fool.com
